Haisco Pharmaceutical Group (002653.SZ): "HSK50042" and "HSK55879" innovative drug IND applications have been accepted for review.

Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Shanghai Haisenno Pharmaceutical Technology Co., Ltd., recently received a "Notice of Acceptance" from the National Medical Products Administration, involving the products "HSK50042" and "HSK55879". HSK50042 is a orally administered, potent, highly selective small molecule inhibitor developed independently by the company, intended for the treatment of respiratory system diseases. Preclinical studies have shown that HSK50042 can effectively improve the pathological symptoms of lung diseases in model mice at low doses, demonstrating good efficacy, tolerability, and a wide safety margin. This application represents a new clinical trial application for HSK50042 tablets in the field of respiratory system diseases, with the potential to provide an efficient and safe new treatment option for respiratory disease patients. HSK55879 is an orally administered small molecule agonist drug independently developed by the company, with proprietary intellectual property rights, intended for the treatment of metabolic system diseases. Preclinical research data shows that HSK55879 exhibits significant pharmacological activity in relevant animal models, with a clear mechanism of action, good tolerability at different doses, and a wide safety margin. Based on existing results, HSK55879 has clear development value and good prospects for translation, offering a potentially efficient and safe new treatment option for clinical patients.